Experienced in Febrile Neutropenia

Qiu Q. Li

Cancer Center And State Key Laboratory Of Biotherapy, 
Chengdu, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Febrile Neutropenia
Cancer Center And State Key Laboratory Of Biotherapy, 
Chengdu, CN 
OverviewLocationsClinical Research

Overview

Qiu Li practices in Chengdu, China. Li is rated as an Experienced expert by MediFind in the treatment of Febrile Neutropenia. Their top areas of expertise are Liver Cancer, Colorectal Cancer, Stomach Cancer, Hepato-Pancreato-Biliary Surgery, and Liver Transplant.

Their clinical research consists of co-authoring 174 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Febrile Neutropenia.

Locations

Cancer Center And State Key Laboratory Of Biotherapy, Chengdu, 610041, China
Other Locations
China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase I, Open-label, Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of KC1036 in the Patients with Advanced Recurrent or Metastatic Solid Tumors
A Phase I, Open-label, Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Preliminary Efficacy of KC1036 in the Patients with Advanced Recurrent or Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 17, 2024
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label, Phase 1, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CMG901 in Subjects With Advanced Unresectable or Metastatic Solid Tumor
An Open-Label, Phase 1, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CMG901 in Subjects With Advanced Unresectable or Metastatic Solid Tumor
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drug: CMG901
Study Phase: Phase 1
View 1 Less Clinical Trial

174 Total Publications

RUNX1/SLAMF3 Axis Drives Immunosuppression to Contribute to Colorectal Cancer Liver Metastasis by Blocking Phagocytosis and Depleting C1QC+ Tumor-Associated Macrophages.
RUNX1/SLAMF3 Axis Drives Immunosuppression to Contribute to Colorectal Cancer Liver Metastasis by Blocking Phagocytosis and Depleting C1QC+ Tumor-Associated Macrophages.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Li's expertise for a condition
ConditionClose
      View All 23 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile